HUTCHMED (China) (HCM) vs Harmony Biosciences (HRMY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Harmony Biosciences (HRMY) has outperformed HUTCHMED (China) (HCM) over the past year, gaining 50.4% versus a loss of 16.6%. Over five years, HRMY leads with a +2.2% price change compared with -57.7% for HCM. HUTCHMED (China) is the larger company by market cap ($2.45 billion vs $2.35 billion), about 1.0 times the size, while Harmony Biosciences is growing revenue faster (+21.5% vs -13.0%).
On valuation, Harmony Biosciences trades at a lower forward P/E (5.8x vs 54.4x for HUTCHMED (China)). HUTCHMED (China) converts more of its revenue into profit, with a net margin of 83.3% versus 18.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCM | HRMY |
|---|---|---|
| Share price | $14.10 | $40.28 |
| Market cap | $2.45B | $2.35B |
| 1-day change | +3.15% | +1.72% |
| YTD return | +2.55% | +7.64% |
| 1-year return | -16.60% | +50.41% |
| 5-year return | -57.68% | +2.23% |
| P/E ratio (TTM) | 141.00 | 12.79 |
| Forward P/E | 54.40 | 5.75 |
| EPS (TTM) | $0.10 | $3.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $548.51M | $868.45M |
| Revenue growth (YoY) | -12.96% | +21.51% |
| Net income (latest FY) | $456.91M | $158.69M |
| Gross margin | 38.68% | 77.16% |
| Operating margin | -7.14% | 24.00% |
| Net margin | 83.30% | 18.27% |
| 52-week high | $16.33 | $43.49 |
| 52-week low | $9.77 | $25.52 |
| Distance from 52-week high | -13.66% | -7.38% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +56.10% | +18.27% |
| Average volume | 68.02K | 896.11K |
| Shares outstanding | 173.81M | 58.24M |
| Employees | 1,790 | 293 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HRMY has outperformed HCM by 67.0 percentage points over the past year.
- HUTCHMED (China) trades at a higher earnings multiple (141.0x vs 12.8x trailing P/E).
- HUTCHMED (China) is more profitable, keeping 83.3 cents of every revenue dollar as net income versus 18.3 cents for Harmony Biosciences.
- Harmony Biosciences grew revenue faster in its latest fiscal year (+21.51% vs -12.96%).
About HUTCHMED (China)
HCM stock →HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,790 employees
About Harmony Biosciences
HRMY stock →Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
HCM vs HRMY FAQ
Which is bigger, HUTCHMED (China) or Harmony Biosciences?
HUTCHMED (China) (HCM) is larger, with a market capitalization of $2.45B compared with $2.35B for Harmony Biosciences (HRMY).
Which stock has performed better over the past year, HCM or HRMY?
HRMY returned +50.41% over the past 12 months, compared with -16.60% for HCM (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HCM or HRMY?
HRMY has the lower trailing P/E at 12.8, versus 141.0 for HCM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are HUTCHMED (China) and Harmony Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.